Literature DB >> 24440671

Interactions between the intestinal microbiome and liver diseases.

Bernd Schnabl1, David A Brenner2.   

Abstract

The human intestine harbors a diverse community of microbes that promote metabolism and digestion in their symbiotic relationship with the host. Disturbance of its homeostasis can result in disease. We review factors that disrupt intestinal homeostasis and contribute to nonalcoholic fatty liver disease, steatohepatitis, alcoholic liver disease, and cirrhosis. Liver disease has long been associated with qualitative and quantitative (overgrowth) dysbiotic changes in the intestinal microbiota. Extrinsic factors, such as the Western diet and alcohol, contribute to these changes. Dysbiosis results in intestinal inflammation, a breakdown of the intestinal barrier, and translocation of microbial products in animal models. However, the contribution of the intestinal microbiome to liver disease goes beyond simple translocation of bacterial products that promote hepatic injury and inflammation. Microbial metabolites produced in a dysbiotic intestinal environment and host factors are equally important in the pathogenesis of liver disease. We review how the combination of liver insult and disruptions in intestinal homeostasis contribute to liver disease.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcoholic Steatohepatitis; Endotoxin; Microbiota

Mesh:

Substances:

Year:  2014        PMID: 24440671      PMCID: PMC3996054          DOI: 10.1053/j.gastro.2014.01.020

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  86 in total

Review 1.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

2.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

3.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

4.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice.

Authors:  Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

5.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

6.  Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption.

Authors:  Guoxiang Xie; Wei Zhong; Houkai Li; Qiong Li; Yunping Qiu; Xiaojiao Zheng; Huiyuan Chen; Xueqing Zhao; Shucha Zhang; Zhanxiang Zhou; Steven H Zeisel; Wei Jia
Journal:  FASEB J       Date:  2013-05-24       Impact factor: 5.191

Review 7.  Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease.

Authors:  R K Rao; A Seth; P Sheth
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-06       Impact factor: 4.052

8.  Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.

Authors:  Tilman M Bauer; Henning Schwacha; Bernhard Steinbrückner; Folke E Brinkmann; Anette K Ditzen; John J Aponte; Klaus Pelz; Dieter Berger; Manfred Kist; Hubert E Blum
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

9.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

10.  Linking long-term dietary patterns with gut microbial enterotypes.

Authors:  Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis
Journal:  Science       Date:  2011-09-01       Impact factor: 47.728

View more
  311 in total

1.  Gastroenterologist perceptions of faecal microbiota transplantation.

Authors:  Sudarshan Paramsothy; Alissa J Walsh; Thomas Borody; Douglas Samuel; Johan van den Bogaerde; Rupert Wl Leong; Susan Connor; Watson Ng; Hazel M Mitchell; Nadeem O Kaakoush; Michael A Kamm
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Enterotoxicity of a nonribosomal peptide causes antibiotic-associated colitis.

Authors:  Georg Schneditz; Jana Rentner; Sandro Roier; Jakob Pletz; Kathrin A T Herzog; Roland Bücker; Hanno Troeger; Stefan Schild; Hansjörg Weber; Rolf Breinbauer; Gregor Gorkiewicz; Christoph Högenauer; Ellen L Zechner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

Review 3.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

Review 4.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

5.  Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration.

Authors:  Stephanie Mathews; Dechun Feng; Igor Maricic; Cynthia Ju; Vipin Kumar; Bin Gao
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

Review 6.  Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery.

Authors:  Michael Kriss; Keith Z Hazleton; Nichole M Nusbacher; Casey G Martin; Catherine A Lozupone
Journal:  Curr Opin Microbiol       Date:  2018-07-20       Impact factor: 7.934

Review 7.  The CF gastrointestinal microbiome: Structure and clinical impact.

Authors:  Geraint B Rogers; Michael R Narkewicz; Lucas R Hoffman
Journal:  Pediatr Pulmonol       Date:  2016-10

8.  Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.

Authors:  Javier Michelena; José Altamirano; Juan G Abraldes; Silvia Affò; Oriol Morales-Ibanez; Pau Sancho-Bru; Marlene Dominguez; Juan Carlos García-Pagán; Javier Fernández; Vicente Arroyo; Pere Ginès; Alexandre Louvet; Philippe Mathurin; Wajahat Z Mehal; Juan Caballería; Ramón Bataller
Journal:  Hepatology       Date:  2015-04-13       Impact factor: 17.425

Review 9.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Pregnancy-specific transcriptional changes upon endotoxin exposure in mice.

Authors:  Kenichiro Motomura; Roberto Romero; Adi L Tarca; Jose Galaz; Gaurav Bhatti; Bogdan Done; Marcia Arenas-Hernandez; Dustyn Levenson; Rebecca Slutsky; Chaur-Dong Hsu; Nardhy Gomez-Lopez
Journal:  J Perinat Med       Date:  2020-09-25       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.